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The splicing factor SF2/ASF is an oncoprotein that is up-regulated
in many cancers and can transform immortal rodent fibroblasts
when slightly overexpressed. The mTOR signaling pathway is
activated in many cancers, and pharmacological blockers of this
pathway are in clinical trials as anticancer drugs. We examined the
activity of the mTOR pathway in cells transformed by SF2/ASF and
found that this splicing factor activates the mTORC1 branch of the
pathway, as measured by S6K and eIF4EBP1 phosphorylation. This
activation is specific to mTORC1 because no activation of Akt, an
mTORC2 substrate, was detected. mTORC1 activation by SF2/ASF
bypasses upstream PI3K/Akt signaling and is essential for SF2/ASF-
mediated transformation, as inhibition of mTOR by rapamycin
blocked transformation by SF2/ASF in vitro and in vivo. Moreover,
shRNA-mediated knockdown of mTOR, or of the specific mTORC1
and mTORC2 components Raptor and Rictor, abolished the tumor-
igenic potential of cells overexpressing SF2/ASF. These results
suggest that clinical tumors with SF2/ASF up-regulation could be
especially sensitive to mTOR inhibitors.
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The PI3K-mTOR pathway is an important contributor to thetransformed phenotype and is activated in many cancers (1,
2). Many components of this signaling pathway are mutated in
tumors, generating activated oncogenes that promote the path-
way (PI3K, AKT) or inactivated tumor suppressors that normally
inhibit the pathway (PTEN, LKB1, TSC1, TSC2) (1, 3). The
importance of this pathway is also underscored by the fact that
specific inhibitors of mTOR can reverse transformation alone, or
more efficiently in combination with cytotoxic drugs; these
inhibitors are currently in clinical trials as anticancer drugs (4, 5).
The PI3K-mTOR pathway is a major contributor to tumor
growth and survival (1, 2). The mTOR kinase is part of two
different protein complexes that result in phosphorylation of
distinct substrates. The mTORC1 complex phosphorylates and
inactivates the translation inhibitors 4E-BP1 and 4E-BP2 and
activates S6K1 to enhance translation (1–3). Enhancement of
translation contributes to tumorigenesis by elevating the levels of
transcription factors with high turnover, such as HIF1-—which
induces metabolic changes leading to aerobic glycolysis, and
enhances angiogenesis (6, 7)—the oncoprotein c-myc (8), -
catenin, and others (9). mTORC2 phosphorylates the oncopro-
tein Akt, which contributes to transformation by phosphorylat-
ing many substrates, leading to inhibition of apoptosis and
enhancement of cell proliferation (10, 11).
We reported recently that the splicing factor SF2/ASF is a
potent oncoprotein that is up-regulated in lung and colon
cancers, and whose gene (SFRS1) is amplified in some breast
tumors; moreover, SF2/ASF can transform immortal rodent cells
when slightly overexpressed, and these cells form high-grade
sarcomas in nude mice (12). We also found that elevated
SF2/ASF expression did not activate the Ras-MAPK pathway,
but changed the alternative splicing of Mnk2 kinase pre-mRNA,
correlating with increased eIF4E phosphorylation downstream
of the MAPK pathway (12). Because activation of the PI3K-
mTOR pathway is seen in many cancers (2, 5), we sought here
to measure the status of this pathway in cells transformed by
SF2/ASF.
Akt, a major effector of the PI3K pathway, is both an upstream
activator of mTOR and a substrate of mTORC2 (2, 3, 13). We
examined the activity of this pathway in cells transformed by
SF2/ASF overexpression. We observed no activation of Akt, but
phosphorylation of substrates of the mTORC1 complex, S6K
and 4E-BP1, was elevated in these cells and was reduced upon
SF2/ASF knockdown. To examine whether the activation of this
pathway is important for SF2/ASF-mediated transformation, we
blocked mTOR pharmacologically using rapamycin and genet-
ically using shRNAs to mTOR, Raptor, or Rictor and found that
all these treatments can block SF2/ASF-mediated transformation.
These results demonstrate the essential role of mTOR acti-
vation in SF2/ASF-mediated transformation and indicate that
mTOR inhibitors may be useful for treatment of tumors with
SF2/ASF up-regulation.
Results
The Splicing Factor SF2/ASF Activates themTORC1 Pathway, Bypassing
Akt Activation. To examine the activity of the PI3K-Akt pathway
in cells with elevated or reduced SF2/ASF, we measured the
phosphorylation state of Akt on S473 by Western blotting. We
did not detect any activation of Akt in any of the cell lines we
examined, including immortal (Rat1, NIH 3T3) and primary
(MEF, IMR90) cells stably transduced with human SF2/ASF
cDNA [Fig. 1 A and C, supporting information (SI) Fig. S1, and
data not shown]. Moreover, knockdown of SF2/ASF in the lung
carcinoma cell line NCI-H460, which overexpresses SF2/ASF
(12), or in NIH 3T3 cells transduced with SF2/ASF did not
inhibit Akt phosphorylation. (Fig. 1B and Fig. S2). These results
indicate that changes in SF2/ASF levels have no effect on
phosphorylation of Akt on S473.
We next measured the phosphorylation state of the mTOR
substrates S6K1 and 4E-BP1 (1). MEF and NIH 3T3 cells
overexpressing SF2/ASF had increased phosphorylation of both
S6K1 and 4E-BP1, and this activation was specific for SF2/ASF,
as cells overexpressing other related splicing factors did not show
comparable activation (Fig. 1 A andD and data not shown). NIH
3T3 cells transformed by SF2/ASF showed increased S6K and
4E-BP1 phosphorylation (Fig. 1C), and tumors derived from
these cells also showed elevated S6K and 4E-BP1 phosphoryla-
tion, compared with tumor-derived cells overexpressing
hnRNPA1 (data not shown). Conversely, transformed cells
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(NCI-H460, HeLa) with knockdown of SF2/ASF showed re-
duced S6K and 4E-BP1 phosphorylation (Fig. 1 B and E).
mTOR Activity Is Required for SF2/ASF-Mediated Transformation. To
assess the importance of mTORC1 and mTORC2 activation for
SF2/ASF-mediated transformation, we took two approaches: First,
we used the mTOR inhibitor rapamycin to block mTOR catalytic
activity as part ofmTORC1, and second, we used shRNAs to knock
down either mTOR itself or Raptor or Rictor, the distinctive
components of mTORC1 and mTORC2, respectively (3, 14, 15).
Colony formation in soft agar by SF2/ASF transductants was
completely blocked by rapamycin, whereas colony formation by
cells transduced with activatedRas or hnRNPA1—another splicing
factor with oncogenic activity (12)—was only partially inhibited
(Fig. 2 A and B). Moreover, rapamycin treatment of NCI-H460 [a
lung carcinoma cell line with high levels of SF2/ASF (12)] also
blocked colony formation in soft agar (Fig. S3).
To examine the effect of mTOR inhibition on tumorigenesis
in vivo, we injected the cells overexpressing SF2/ASF into nude
mice, and after small tumors developed (200 mm3), we treated
the mice daily with rapamycin (4 mg/kg, i.p.) and measured the
change in tumor volume (Fig. 2 C and D). Rapamycin treatment
caused shrinkage of the tumors overexpressing SF2/ASF, and
complete remission for most of the tumors (Fig. 2C). The growth
rate of tumors expressing activated Ras also decreased, but no
tumor shrinkage was observed (Fig. 2D). This experiment shows
that cells overexpressing SF2/ASF are highly sensitive to rapa-
mycin in vivo.
To examine the contribution of mTORC1 and mTORC2
to SF2/ASF-mediated transformation, we designed specific
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Fig. 1. SF2/ASF activates mTOR, bypassing Akt activation. (A) MEF cells were infected with transducing retroviruses encoding the cDNAs of four splicing factors from
the SR protein family (SF2/ASF, SRp55, SC35, and SRp30c) and the hnRNP A/B protein hnRNP A1, fused to a T7 tag at the N terminus, or with the pBABE vector alone.
After selection, the cells were plated (106 cells per 10-cm plate) and lysed in SDS sample buffer after 24 h. Western blots were carried out by using the indicated primary
antibodies.Theantibodytophospho-S6K1recognizesbothp70andp85,whichdifferbytheir translation initiationsite (27). (B)NCI-H460 lungcancercells,whichexpress
high levels of SF2/ASF, were infected with empty retroviral vector (LMP) or LMP encoding SF2/ASF-specific shRNA (shSF2–1) or a control shRNA with two mismatches
(shSF2-m). After selection, cells were lysed as above. Western blots were carried out by using the indicated primary antibodies. (C and D) NIH 3T3 and MEF cells were
transduced as described in A, and lysed after selection. Western blots were probed with the indicated antibodies. (E) HeLa cells were transfected with the indicated
siRNAs and lysed after 72 h. Western blotting was done as in D. The 4E-BP1 phosphorylation in C–E is detected by its mobility shift toward the  form (28).
A B C D
Fig. 2. mTOR activity is required for SF2/ASF-mediated transformation in vitro and in vivo. (A) Quantitation of colony formation in soft agar of NIH 3T3 cells
transduced with SF2/ASF, hnRNP A1, or oncogenic Ras, in the presence of rapamycin or vehicle control, as indicated. Mean values in the absence of rapamycin
were set at 100%; error bars indicate standard deviations (n 3). (B) Representative fields of soft-agar colonies described in A. (C) NIH 3T3 cells transduced with
SF2/ASF were injected into nude mice. Tumors were allowed to reach a size of 200 mm3, and then mice were injected i.p. with 4 mg/kg rapamycin or vehicle
control every day. (D) NIH 3T3 cells transduced with RasV12 were injected, and mice were treated as in C. Tumor volumes were measured during the treatment.
Animals were killed when tumors reached a size of 1,500 mm3. Error bars in C and D indicate the top halves of the standard deviations (n  10).
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shRNAs to stably knock down mTOR, Raptor, or Rictor in the
cells overexpressing SF2/ASF (Figs. 3A and 4A). Knockdown of
any one of these three factors completely abrogated the tumor-
igenicity of cells overexpressing SF2/ASF (Figs. 3 B and C and
4B). We conclude that mTOR activation is essential for SF2/
ASF-mediated tumorigenesis.
Discussion
mTOR activity is regulated by a complex signaling network that
senses nutrient and energy levels, growth factors, and stress
signals like hypoxia (2, 3). One major pathway that regulates
mTOR activity and is activated in many tumors is the PI3K-Akt
pathway, which inhibits the GTPase activity of the TSC1/2
complex, leading to the activation of the mTOR activator RheB
(2, 3). The PI3K-Akt pathway also inhibits the mTOR inhibitor
PRAS40 (16). We found recently that the splicing factor SF2/
ASF is a protooncogene that is up-regulated in many tumors and
modulates alternative splicing of the mTOR substrate S6K1 (12).
This alternative splicing effect is downstream of mTOR and is
not affected by the mTOR pathway (data not shown).
Here, we examined the activity of the mTOR pathway in cells
that were transduced with human SF2/ASF cDNA to achieve
modest overexpression of this splicing factor [Fig. 1A; (12)]. We
found that increased SF2/ASF promotes phosphorylation of the
mTORC1 substrates S6K1 and 4E-BP1, whereas SF2/ASF
knockdown inhibits these phosphorylation events (Fig. 1). In-
terestingly, we observed no enhanced Akt phosphorylation in
mouse, rat, or human cells overexpressing SF2/ASF (Fig. 1 and
Fig. S1). Thus, we conclude that SF2/ASF activates mTOR
downstream of Akt. In addition, because Akt is also a substrate
of the mTORC2 complex in a feedback loop (17), we infer that
mTORC2 is not activated by SF2/ASF.
We do not know at present the exact mechanism(s) by which
SF2/ASF activates mTORC1. The effect could be indirect,
involving alternative splicing of an upstream activator or inhib-
itor of mTOR, for example, or it could be the consequence of a
direct interaction between SF2/ASF and mTOR. Relevant to the
first scenario, we found recently that SF2/ASF induces the
expression of a new S6K1 splicing isoform (‘‘isoform-2’’) lacking
the C-terminal region phosphorylated by mTOR and that this
isoform is oncogenic (12). An intriguing possibility is that
isoform-2, in a positive feedback loop, might somehow activate
BA
C
Fig. 3. mTORC1 is required for SF2/ASF-induced tumorigenesis. (A) NIH 3T3 cells transduced with pWZL-Hygro-SF2/ASF were supertransduced with retroviruses
encoding mTOR- or Raptor-specific shRNAs. After puromycin selection, cells were analyzed by Western blotting for mTOR and Raptor protein expression; antibodies
to SF2/ASF (which detects endogenous and tagged proteins), SRp55, and -catenin were used as controls. (B) Cells described in A were injected into nude mice, and
tumor volume was measured every 3 days, as described in Fig. 2C. Error bars indicate standard deviations (n 10). (C) Representative mice described in B are shown.
A B
Fig. 4. Both Raptor and Rictor are required for SF2/ASF-mediated transfor-
mation. (A) NIH 3T3 cells transduced with pWZL-Hygro-SF2/ASF were super-
transduced with retroviruses encoding Raptor- or Rictor-specific shRNAs or
with the empty LMP vector. After puromycin selection, cells were analyzed by
Western blotting for Rictor and Raptor protein expression; antibodies to actin
were used as controls. (B) Cells described in A were plated in soft agar in
duplicate experiments. Colonies were counted 14 days later. Error bars indi-
cate standard deviations (n  2).
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mTORC1. Regarding the second scenario, recent studies
showed that SF2/ASF can activate translation initiation in a
cell-free system, probably independently of its splicing activity
(18, 19). In addition, SF2/ASF was shown to be present in a
complex with mTOR and to enhance 4E-BP1 phosphorylation in
translation extracts (20). Moreover, the translational-stimulation
effects of SF2/ASF depend on the presence of 4E-BP1 and are
sensitive to rapamycin, indicating that activation of mTORC1 is
responsible for these effects (20) Our results in cells are con-
sistent with these recent findings in extracts (Figs. 1–3).
To examine the importance of mTOR activation for SF2/ASF-
mediated transformation, we blocked mTOR activity either phar-
macologically, using the mTOR-specific inhibitor rapamycin, or by
RNA interference against mTOR itself, against Raptor, the dis-
tinctive component of mTORC1 (Figs. 2, 3), or against Rictor, the
distinctive component of mTORC2 (Fig. 4). We used Ras-
transformed cells as a control; Ras activates both the PI3K-Akt and
the Raf-MAPK pathways, both of which contribute to transforma-
tion (21, 22). Thus, blocking the mTOR pathway should only
partially inhibit Ras-induced transformation. Indeed, we found that
rapamycin partially inhibited colony formation in soft agar, as well
as tumor growth in nude mice, of Ras-transformed cells (Fig. 2 A,
B, and D). In contrast, cells transformed by SF2/ASF were ex-
tremely sensitive to rapamycin, both in vitro and in nude mice (Fig.
2A–C). These results indicate that mTOR activation is essential for
SF2/ASF-mediated transformation.
Our results further show that mTORC1, but not mTORC2, is
activated by SF2/ASF, as determined by measuring the extent of
phosphorylation of their unique substrates (Fig. 1 and Fig. S1).
Consistent with SF2/ASF’s activation of mTORC1, we found
that knockdown of Raptor or the mTOR kinase itself caused
complete inhibition of tumorigenesis of cells transformed by
SF2/ASF, indicating that mTORC1 activation is an essential step
in SF2/ASF-mediated transformation.
Interestingly, knockdown of Rictor, the distinctive component of
mTORC2, also led to inhibition of colony formation in soft agar
(Fig. 4), indicating that although mTORC2 is not activated by
SF2/ASF, its basal activity is still required for SF2/ASF-mediated
transformation. mTORC2 phosphorylates Akt on serine 473, and
Akt activity regulates many survival pathways (11). Thus, inhibiting
Akt phosphorylation throughRictor down-regulation is expected to
inhibit the oncogenic potential of many transformed cells.
Many studies have shown activation of mTORC1 in tumors (17).
However, it was not clear whether the components of mTORC1,
mTOR, and Raptor, have direct roles in transformation. Rapamy-
cin, which has antitumor activity, blocks mainly mTORC1 activity,
but recent data showed that it affects the stability of mTORC2 as
well (23). Our results, based on rapamycin sensitivity andmTORor
Raptor knockdown, suggest that mTORC1 activation is essential
for SF2/ASF-mediated transformation. SF2/ASF-transformed cells
proved to be extremely sensitive to mTOR inhibition, raising the
possibility that clinical tumors with SF2/ASF up-regulation will be
especially sensitive to mTOR inhibitors. If this proves to be true, it
might facilitate the diagnosis and treatment of cancers with SF2/
ASF overexpression.
Materials and Methods
Cells. HeLa and MEF cells were grown in DMEM, and NCI-H460 cells were grown
in RPMI 1640 medium, supplemented with 10% FCS, penicillin, and streptomycin.
NIH 3T3 cells were grown in DMEM supplemented with 10% calf serum (CS),
penicillin, and streptomycin. To generate stable transductant pools, NIH 3T3 and
MEF cells were infected with pBABE-puro or pWZL-hygro retroviral vectors (24)
expressing T7-tagged human splicing factor cDNAs. At 24 h after infection, the
mediumwas replaced,and24h later, infectedcellswere selectedwithpuromycin
(2g/ml) or hygromycin (200g/ml) for 72 h. In the case of double infection with
LMP-puro-shRNAs vectors, NIH 3T3 cells transduced with pWZL-hygro-SF2/ASF
virus were selected with hygromycin for 96 h, followed by infection with the
indicated LMP-puro-shRNAs viruses and selection with puromycin for 72 h.
RNA Interference. For inhibition of SF2/ASF and PP2C expression, HeLa cells
were seeded (7104 cells per well) in six-well plates in antibiotic-free medium.
At 24 h, cells were transfected with 200 pmol of siRNA per well (Dharmacon),
by using Oligofectamine (Invitrogen). At 72 h, cells were lysed, and protein
and RNA were extracted as described below. siRNA target sequences: TTGAC-
CACTGAAGAAGTCA (PP2C) and ACGATTGCCGCATCTACGT (SF2/ASF); both
siRNA strands had 3 dTdT tails. shRNAs against mouse and human SF2/ASF
were as described (12). NCI-H460 and NIH 3T3 cells were transduced and
selected as described above.
shRNA Sequences. Raptor sh1: TGCTGTTGACAGTGAGCGATCGTG-
GCAAGTTTGTTTAGAATAGTG AAGCCACAGATGTATTCTAAACAAACTT-
GCCACGAGTGCCTACTGCCTCGGA. Raptor sh2: TGCTGTTGACAGTGAGCGAG-
GCGTTCCTTCTGTGGTCAAATAGTG AAGCCACAGATGTATTTGACCACAG-
AAGGAACGCCGTGCCTACTGCCTCGGA. mTOR sh1: TGCTGTTGACAGTGAGC-
GAAGCAGGGACTCAGAACATAAATAGT GAAGCCACAGATGTATTTATGTTCT-
GAGTCCCTGCTGTGCCTACTGCCTCGGA. mTOR sh2: TGCTGTTGACAGTGAGC-
GAACCACGTTGTATCTGAGTAAATAGTG AAGCCACAGATGTATTTACTCA-
GATACAACGTGGTGTGCCTACTGCCTCGGA. Rictor sh1: TGCTGTTGACAGT-
GAGCGCTAGGTGTTTAAGACTATTAAATAGTG AAGCCACAGATGTATTTAAT-
AGTCTTAAACACCTATTGCCTACTGCCTCGGA. Rictor sh2: TGCTGTTGACAGT-
GAGCGACTCCAGCAAACTTGTAAAGAATAGTG AAGCCACAGATGTATT-
CTTTACAAGTTTGCTGGAGCTGCCTACTGCCTCGGA.
Immunoblotting. Cells were lysed in SDS and analyzed for total protein con-
centration as described (25). Thirty or 50 g of total protein from each cell
lysate was separated by SDS/PAGE and transferred onto a nitrocellulose
membrane. The membranes were blocked and probed with antibodies by
using enhanced chemiluminescence detection. Primary antibodies: -catenin
(1:5,000; Transduction Laboratories, or 1:2,000; Sigma); SF2/ASF [AK96 culture
supernatant 1:100 (26)]; T7 tag (1:5,000; Novagen); S6K1 (N terminus) (1:200;
PharMingen); and Raptor, Rictor, mTOR, phospho-4E-BP1 T70, 4E-BP1, phos-
pho-S6K T389, phospho-ERK (T202/Y204), and ERK1/2 (1:1,000; Cell Signaling
Technology). Secondary antibodies: HRP-conjugated goat anti-mouse or anti-
rabbit IgG (HL) (1:10,000; Pierce).
Anchorage-Independent Growth. Colony formation in soft agar was assayed as
described (12). Rapamycin was added once to the top medium at the indicated
concentrations. Plates were incubated at 37°C and 6% CO2. After 10–18 days,
colonies from 10 different fields in each of two wells were counted for each
treatment, and the average number of colonies per well was calculated. The
colonies were stained as described (24) and photographed under a light
microscope at magnification 100.
Tumorigenesis Assays in Nude Mice and Rapamycin Treatment. NIH 3T3 stable
pools expressing SF2/ASF or H-RasV12 were injected (2 106 cells per site in 200l
of PBS) s.c. into each rear flank of (NIH nu/nu) nude mice by using a 26-gauge
needle.After small tumorsappeared (100–200mm3),micewere injecteddaily i.p.
with 4 mg/kg rapamycin in 2% Tween 20, or just with vehicle. Tumor growth was
monitored as described (12). For shRNAs experiments, NIH 3T3 cells expressing
both pWZL-hygro-SF2/ASF and shRNAs to mTOR or Raptor (see sequences above)
were injected, and tumor volume was monitored as described (12).
Statistical Analysis.Where appropriate, the data are presented as the means
SD. Data points were compared by an unpaired two-tailed Student’s t test, and
the calculatedP values are indicated in the figure legends. For soft-agar colony
assays, means  SD and P values were calculated for 10 fields per well, in
duplicate wells for each transductant pool.
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